First-Line Treatment of Advanced/Metastatic NSCLC

Jonathan W. Goldman, MD

Disclosures

October 10, 2022

Over the past decade, the ability to target specific oncogenic drivers has transformed the treatment of advanced or metastatic non–small cell lung cancer (NSCLC).

Dr Jonathan Goldman, of UCLA Medical Center, discusses the range of mutations identified in NSCLC, including EGFR, ALK, KRAS G12C, MET, BRAF, and fusions including ROS1, RET, and NTRK.

Dr Goldman compares different options for gene testing and discusses how the utilization of tumor testing still varies greatly despite the availability of targeted therapies.

Finally, he explores the range of approved first-line therapies used to target commonly identified mutations.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....